Tipsheet
What matters at India’s listed companies
Earnings · Finance - Lending · Micro cap

Goldline Pharmaceutical's profit jumps 45% to ₹411.71 lacs in FY26

The nano-cap drugmaker's first full-year audited results show profit outpacing revenue growth. Revenue rose 11% to ₹3,119.76 lacs.


Mkt cap₹32 cr
P/E271.61×
ROE0.33%
Debt / eq.0.01
₹411.71 lacs FY26 net profit, up 45% from the prior year.

What's new

  • Net profit rose 45% to ₹411.71 lacs for the year ended March 31, 2026.
  • Revenue grew 11% to ₹3,119.76 lacs.
  • The board appointed an internal auditor alongside approving the results.

Why this matters

This is the first full-year audited result for Goldline, a recently listed nano-cap. The 45% profit jump on 11% revenue growth points to lower costs or better pricing. The unmodified auditor's report provides a clean baseline for a company still proving itself.

What we're watching

  • Whether the profit surge holds in coming quarters or reflects one-off items.
  • How the new internal auditor influences governance at this early stage.
  • Growth trends from a small revenue base.

The full read

Goldline Pharmaceutical, a recently listed nano-cap, posted 45% profit growth in its first full-year audited results. Net profit hit ₹411.71 lacs for FY26, up from ₹283.43 lacs the prior year. Revenue grew 11% to ₹3,119.76 lacs, meaning the bottom line outpaced the top line by a wide margin. That points to improved profitability for the small drugmaker. The auditor's report is unmodified. The board also brought on an internal auditor, a standard governance move for a newly public company. The filing adds little beyond the numbers, but it sets a clean financial baseline for a company still proving itself to the market.

Questions answered

What were Goldline Pharmaceutical's headline numbers?
For FY26, the company reported a net profit of ₹411.71 lacs, a 45% increase from the prior year's ₹283.43 lacs. Revenue grew 11% to ₹3,119.76 lacs.
Why did profit grow much faster than revenue?
Net profit expanded 45% while revenue grew only 11%, which indicates improved profitability, likely from cost control or better margins on its sales.
What did the board do besides approve results?
Along with the financials, the board appointed an internal auditor for the company.
Is this a significant event for the company?
It establishes the first clean, audited full-year benchmark since Goldline's listing. The auditor's report is unmodified, adding credibility to the numbers.
Mentioned: Goldline Pharmaceutical Ltd. · ₹411.71 lacs net profit · ₹3,119.76 lacs revenue
Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.